Revvity (RVTY) 1 Feb 242023 Q4 Earnings call transcript

Hello, and welcome to today's Revvity Inc. Q4 2023 Earnings Conference Call. My name is Bailey, and I will be the moderator for today's call. [Operator Instructions] I'd now like to pass the conference over to our host today, Steve Willoughby, Senior Vice President of Investor Relations. Please go ahead.

operator. you, Thank and Conference everyone, Revvity's Quarter Fourth Good welcome Earnings Call. XXXX morning, to

call are our On President me with the today Executive and Financial and President and Prahlad Officer; Max Vice Krakowiak, Senior Chief Officer. Chief our Singh,

risks be are remind Any forward-looking or and like in to to statements have our statements, or objectives, suggested if views not update filings. actual also these uncertainties. The forward-looking filings. our those begin, due company's future, differ in the issued release comments discussed change. we of our this Statements our statements to statements today. in we variety SEC today financial include, the safe everyone made projected obligation of made call may Before intentions. earlier as certain disclaim results but factors, even outlined of plans, in of limited press or These We company's in necessarily a I'd harbor matters detail estimates which projections and our that represent significantly involve this may other expectations statements on which or may morning from the SEC forward-looking those are to any

rely today's any our views date So on as any you statements should of after not of as representing today.

Prahlad this release. I'll to reconciliation During Chief our is this during to call, the comparable President the it to now non-GAAP of non-GAAP A as measures Prahlad? Officer, we turn over to financial plan earnings available measures. referring attachment GAAP will use Executive call and be most financial an Singh. we to press our certain measures directly

everyone. good and Steve, you, morning, Thank

than the year, few revenue. in continued we our with had while finished of fourth decline and better to quarter pre-announcement non-COVID a we the we end ago, the in perform headwinds weeks slightly X% organic able highlighted anticipated As a industry were throughout

that say I each than I performance were performed as quarter in expected. region on had and above to our both in would we broad-based a slightly Sciences that will as what our better would provide the highlight details more performed Max geographically Life major our stronger-than-anticipated balanced also While assumed. bit, results segments line well was Diagnostics

job helped did also with control upside challenging deliver of tightly EPS good that fourth a year-end, along favorable in continuing persisted our additional to onetime We quarter. the expenses through benefits, tax some in environment and the light

capital the million We also flow, had while in a free initiatives. deployment $XXX our of strong very quarter nearly continuing cash flow cash on execute with to

we For generated the X% year growth. XXXX, organic non-COVID full

dust at the the broader While performance once not the settles. peer differentiated see we what be will for the versus industry near the high our will likely think I end hoped year, the of for and was year set start the that of you fully

to financial We for forward, provided over continue demonstrated recently going we new expect the differentiated in our performance years. this as framework coming the performance financial expected

our growth at and the now that growth all normal a anticipate end X% As broader operate we In industry in, operating basis XXX part now we post-COVID the revenue of above performance margin outlook, to expect level world this to be the organic be organic expect to expansion long-range result growth to continues overall. would annually. this regardless the points In year, XX macro we of this basis X% Revvity's in industry, we of result new points of environment. high will of in

range mid-single-digit that the own X% of years, conference, to business of our Life As company. for we their the Sciences to expect growth and is business we coming the grow during XX% a over highlighted reagents generating approximately Software recent total our XX% comprised immunodiagnostics, investor Signal on in

of see to they expect as precision of also the Omics the well and continue With has overall infectious the in profitability that natural and involved increasingly stronger therapy, some time. Revvity extremely these is and areas on it higher-growth capitalize we [ stand as result ] and of the margin unique expansion over on the to become going medicine. our company. within as tuberculosis an other such they remainder as some continue such emerging cell company development, future, segments, to business, most think of larger as you grow the company we clinical gene are last diagnostics, where over planning in years become than Given out of a Revvity to in and of We're several most diseases. very piece multi the positioned the pharmaceutical I exciting will research areas durable faster autoimmunity, what will

differentiated operating a screening turnaround it CIVD customers, complete novel more faster with a to steps the The and solution in hands-on a the which also and plastic perfectly innovative sample newborns. answer portfolio launch than in less in first-of-its-kind results needed continuous newborn The and and the a new consumables and as this from we from existing of both PCR EONIS-Q sustainability time is workflow, of methods. equipment and introduction which product timed This position are for innovation wear in specialized a significantly new is a our perspective. with diagnostics diagnostic in with our fewer a have consists system a It We is and workflow, allows attractive sciences kit. With example and involvement costs greater testing categories compete. EONIS-Q was business. A dedicated of required. commercial approach molecular competitive for new lower in good quarter being this within life and unique solution, muscular atrophy software streamlines SCID fourth the of a our which spinal system no

mandates for SMA Screening should Newborn newborns going XXXX, Alliance screened by European be Spinal in Europe Atrophy the all in As Muscular that, for forward.

benefiting continuing market to cutting-edge bring both they serve. innovative customers we patients Our how our the to solutions and, are ultimately, company, new system across just is of the one EONIS-Q and example from

went our earlier have on been in platform, to operational making new to e-commerce than is the design approximately A We good It platform's of months initiatives. the U.S. we extremely business operating of also our for consumer-friendly, which while live revenue our mid-December, this be synergies. example expected was built has in over specifically delivering become. of X X good the needs launch integrated progress is and anticipated. The both what also, time,

outside expect system in live the XQ. early to this We U.S. new go

agility is is sole-source one antibody Horizon, would use. occurring from scale Through possible of and how, in Revvity. our was batches. their for replacement example and have I'm I'm The had we that our ability in Another be to proud the of A the for year, within and quality in never we scientists EUROIMMUN, assays thing company were supplier diagnostics BioLegend and it to a have company. rapid have this own collaboration strong amongst validated extremely companies great the see across antibody, weeks, manufacture our possible most teams been at begin commercial developed collaboration not the amongst inconsistencies last the able sure sufficient X it would it than to today past, of other

customers continue, spending working levels through we still their years. expect As biotech half to the the impact the elevated the first and year, as in ongoing the from our particularly are this during ahead year, of we to headwinds COVID pharma from look they

well we will as for this continuing assuming year begin challenges are anticipating the returning of the as market to return some stabilize the half when We reduced costs end growth company that XXXX overall. In into to of of in of XXXX. dynamic light pressure variable we're back the in the the

have operating approximately temporary implemented into to this year-over-year We low margins organic to to growth allow remain repeat protect We flat we cost at through anticipate profitability XX% our additional period. actions despite expect strong these recently for will actions year, XXXX. structural the our single-digit this

a have capitalize on to the further company streamline have when a and to be year we sitting on with we industry we for potential result XXXX, exists we put differently The have combined of to in coupled the range in full to years, additional large EPS positions us optimize leverage in early company. XXXX. on looking XXXX say the to our still ago. actions up divestiture strongly order significant in We once number than the anticipated adjust business significant our XXXX, with adjusted completed in our as over took quite playing implemented growth operations us Overall, being areas good this also expect our potential past a to the begin ended many back trajectory normalizes. our now we when reach that several had $X.XX. With measures become. as further to the of here XXXX, certainly it out acquisitions $X.XX We It in I'd

undergone few However, ultimately last I'm we years, which transformation so the past that proud have the we of completed over year.

external what not in that it well to and as that period a of now extremely company, would ] become and many have I'm we differentiated of who the fruition. of made While so efforts grateful XXXX everyone's [ to face the report are Without challenges, and come of Revvity continuing the efforts our significant headwinds will stronger call human confident have from unique potential company boundaries science. With Max. industry the of over performance been we through positioned possible. I'll the help remains We expand to turn to remain that, emerge temporary this has

quarter fourth continued company a these of good everyone. during team's in allowing demand morning, industry despite performance remain which and continuing expectations our in quarter. exceed our the period I perseverance results for through year-end, to our demonstrated Thanks, to the Prahlad, dynamic. underlying am proud The its challenges

in pressure in continue assuming look which bit, cause full expectations through largely our results at the environment our As first what place similar to a more will I'll current of we now year, remains year to this half and comment in achieved fairly we XXXX. market on put least on to are the

XXXX we to would the of in second the expect saw with remaining of However, revenue declines to last we returning first inverse organic our of year the and what half. growth before be half facing performance challenged somewhat

period, already our this have this and the single-digit normalizes. actions structural outlook, control. far extremely last we anticipate efforts so which within that despite future to those when low While throughout way in fully implemented our leverage and, cost at this growth operating flat paving margins have as are remain through work dynamic operating on expense we XX% for progressively to year, allow management year, additional we remain we tightened We continued items more our the previously measures our significant focused greater mentioned, growth will year

and also with inventory and collections flow management. as good XXXX. generated We the balance we fourth cash our free progress $XXX million quarter, in on made we flow cash of sheet meaningful progress In made

we generated we will Excluding $XXX free be which much back incurred overall. us million divestiture-related XXXX, of of over XXXX, year, in the outflows during in flow coming to cash the

the are performance the occurred positioned I view deployment of very this this change on past and year, initiatives capital executing has the well amount to year. we our continue Given that at company strong over as

Sciences generated incremental X% of fourth Life in our expectations contribution tailwind the million Now $XXX of again the moving our organic we guidance. FX specific end was full was outperformance to above non-COVID our for the had our quarter, decline slightly which a Overall, segments The no quarter acquisitions. a high quarter. Diagnostics fairly year performed as total both X% our from broad-based and and was in adjusted revenues results. revenue, in above the and company resulting

which $X non-COVID early FX million revenue, For billion adjusted X% growth, from from year, in of and COVID. impact total comprised a year M&A generated the the full contribution modest was we organic or $X.XX no of

our P&L, As adjusted it to quarter, generated expectations. margins which the in relates we in XX.X% were with line operating our

margins year, points favorable in quarter, approximately which XX%, op a pricing points brought full full of removal XXX revenues. from impact approximately to approximately basis XXX of points. excluding incurred pricing were expansion, basis which year the of For COVID-related our the XXX We impact basis the the represented

expect at We favorable basis XXX forward. going annually continue least pricing to points of

adjusted of our which we $XX largely net other with line, in and expense line million, expectations. had was the below interest Looking

interest net million. other adjusted expense was the $XX and For our full year,

discrete adjusted few a basis favorable by a EPS to rate Our contributed couple quarter. $X.XX which to points tax in favorable our XX% due the was These tax approximately was items onetime quarter, of the in tax our to hundred expectations items.

quarter, was was in would averaged adjusted the the led full with our quarter and $X.XX XXX.X outstanding tax incurred million line the $X.XX, in above do XX% for XX.X%, not we expectations. EPS $X.XX the have and in year. million fourth in end future. shares the which of the our in the XXX.X which above repeat to been excluding here adjusted quarter This expectations, to full and the high favorability our fourth For of the we all but rate midpoint We year, approximately expect

XXXX adjusted was $X.XX. full-year Our EPS

I from cash full-year mentioned, on a activities. basis, generated flows positively Moving million these as beyond $XXX while headwind our expect as outflows million XXXX a previously Also, quarter, of $XXX flow come free which we includes impact over cash divestiture onetime our they when the portion and slightly we investing million, free in the a P&L, flow of to in us. large was and have of I rebranding-related cash to reverse back $XXX mentioned,

now we We sheet, $XXX maturities We business in decline grew commentary fourth digits now the and we quarter in additional coming to a September million single will mature Life Europe we organic Investor single for the fourth digits We capital will aligned presentation and shortly which over some comprised million decline the and leverage in flat in revenue As continue U.S. on quarter the non-COVID million balance included in overall. the to debt. the declined was our bond with of EBITDA bond the Geographically, due trends, we digits due purchased our single high that extinguish will adjusted declined slide our an to website. use finished which quarter is also in China quarter. X% full Diagnostics. with ratio in quarterly before in X% in of to year net remainder Relations of our low Asia, segment debt this have provide X.Xx. I September. remain deployment, on active in low Sciences treasuries with of treasuries, a The in have $XXX of $XXX the on this comes growth X% the in Americas, our

Americas Within quarter, offset grew organic China year. year, digits, in Life in mid-single high single performance digits, X% full Europe Asia full grew with we single-digit China the high achieved Sciences. X% mid-single declined in in growth in we Life growth the and For with in single-digit The non-COVID flat and growth growth Diagnostics immunodiagnostics mid-single-digit both digits and Sciences. by decline for Diagnostics, a the experienced low

For in adjusted X% Diagnostics China our basis. organic Sciences. From revenue and million in on a mid-single-digit the a overall, business single-digit mid-single organically growth growth in the full Science quarter. low double-digit digits growth of Life perspective, basis year, Life grew with on total in $XXX immunodiagnostics and high This in an X% generated segment the was down reported

Life for by the year, quarter customer in in and mid-single the declined the perspective, flat and For mid-teens growth in the a digits biotech full growth the for pharma single-digit which the mid-teens in customers year, the our sales customers Sciences offset high was the organically. From was year. from business government and quarter academic in

was for the quarter in down down mid-single the Life and XXXX digits in Sciences Life the about teens revenue year. revenue and high XX% Our total of instrument represented Science in

licensing and about of services revenue digits year. in grew pharma Sciences represented XX% the specialty the mid-single and in single reagent in digits the low revenue and Life XXXX quarter for Our

with quarter software The Finally, XX% both and which the quarter represented of double renewing, the Science driven year. revenue year which decline the our fewer line for Signal full digits remaining business, expectations single in digits on revenue segment was basis. multiyear in of Life which quarter the grew high a in in non-COVID for by XXXX, was and the in declined X% contracts normalize the X% on quarter, $XXX an ago and we in reported X% basis, On down our was basis year million and a a segment, organic Diagnostics and the the anticipate year. in the we versus total the adjusted XXXX. In in to generated X%

year. of XX% about revenue organically, COVID, total the both grew represented the and the business in immunodiagnostics in full mid-teens XXXX quarter Our our excluding diagnostics during and

as teens globally grow business in the China, of both it the year. and Our in full immunodiagnostics quarter strong continued was the outside to high

the which in the Our Omics decline organically was our total business in lab digits of single significant XXXX, year. represented by XX% This declined a mid-XX% business and again nearly quarter about Revvity Diagnostics health the revenue in in the pressured the low reproductive business, and for decline full full quarter in XX% year.

XXXX, offset the to in performance year. now by continue. will franchise, our single overall last transition contract newborn digits not lapped year-over-year have for pressures anticipate we the we from which XXXX the high As growth such pressured partially and major do were to These grew in completions, which strong year declines

revenue revenue see XX% which in in roughly the our lab the to the our XXXX, was quarter the of single clinical Diagnostics spending applied business in genomics down in effect remaining full and pharma and slowdown Finally, spending. Non-COVID COVID elevated the applied hangover for total during down genomics high biotech mid-teens was organic the the business, for from from represented year. pressure continue digits

remain as XXXX, Now current as year our we industry expect comparisons the progresses. easier headwinds quarters to over face to least of to outlook begin for we couple the next before at pertains it

guidance for X% expect growth down XXXX revenue range. resulting initial the a mid-single be digits similar in perspective, first with down a year-over-year half in we second in being quarter, quarterly to Our the in organic experienced is in we to sequential quarter what first overall. improvement X% From pacing to the the still

return in quarter positive to third the starting expect growth We year. to this

to the of FX based rates at We to December. contribute X% on the also approximately end revenue, expect total

Moving down the P&L.

expect we for XX% flat recent variable cost our organic our the returning We both some operating structural actions this at offset help cost will growth hold as expect to lower-than-normal margin and year.

our for it will result when combined the with XXX expect first in cost be our actions, revenue partial we total from in operating the the several in fairly of the points expect which our lowest full quarter impact each to the margins first being only quarters average, to recent at the margins quarter basis below year in year, year. guidance quarter quarter be being fourth the quarter. other the our similar here around currently expect year strongest overall to and full with third our We the We second

other attributed in approximately lower $X.X net representing This pay to billion XX% in $XX on we in income is versus year. XXXX. XXXX XXXX as last We increase interest million, adjusted balances increase be interest expect to cash debt less and a off expense and

expect to similar to share XX% This and was what to adjusted quarter. we it be million, in what our the in count of be be EPS results midpoint $X.XX rate our to being flat to initial the to $X.XX, guidance the range XXX.X all generated We average XXXX tax in fourth with our XXXX. in

approximately earnings be rate will average to be about fourth the quarter tax of expect first as net quarter increasing year. points our XX% from about sequentially the the million XXX expense $X the full our basis remainder our year down in here full of will above We year interest before and come over

will up the potential XXXX, those reducing take Revvity have to of operator, pipelines, capital manage to to optimize the like as our full stronger its ensure delivering we our active headwinds capitalize further following to with while enter questions. continuing in and transformation. With appropriate current that we an streamline working this call innovation become. subside, for we fully actions on even we what items would our closely company to With that, we are position will the and within such highlight recovery, realize differentiation control, continue our deployment, open on and industry As be capital now remaining

Nephron Meehan first today of Our Jack the Instructions] question comes from line [Operator Research. from

business your how visibility to about still Prahlad, The pretty and into wanted thoughts the you're macros now. feeling just volatile. get start

hear great you're be your would is customers this right the things it build confidence that and from to hearing XXXX in the outlook Just what spot.

challenging, not while out it including or 'XX, had anticipating look first see trends. not quarter, not I a I mean, environment or in to did significant I the forward sort improvement, others more 'XX remained the certainly envisioned current into deteriorate play as rather did the fourth as we of would it has meaningful for good but But than say, in the time more 'XX, we I think here of what first anticipated. continuation that, had any say we quarter, in we would it. of was are

So to more things would provide would I current upside pick that do outlook. to that up. start say to the I expect

are temporary currently comes trough. we of demands where pattern a more we somewhat more holding a backs, experiencing optimistic of that So what before perhaps but are are is I'm we is

go, have that we the one us portfolio that journey as the gone things is through. think transformation far do As I we of help

meaningful have pretty are you at capital-intensive more a portfolio have allows the look our got we business and of spot. If that this than than got differentiation diagnostics peers. we've a in peers, our We've us now, our now a decent business, confidence less to software we

And a then for follow-up Great. Max.

Just I you as -- appreciate color pacing provided. the you the on

look about, this If there get sales, first assuming else wanted noteworthy talking assuming so of is ramp behind the of you're you're comp terms at you just to core the confirm, in in down quarter, are like assumptions anything Or that? kind the you mid-singles dynamics? to is I to just just

Yes.

comps So it. driving definitely of majority the is

a down annual that wouldn't of half, in there's way material both mentioned. cadence but third but nose, and to quarterly we And slight about between a it's say second are So a a previously you comp-driven. still if half, always growth remarks, digits QX, are in I look stack in second think our with change bit low X-year in expecting environment first is little at at single the mostly that half it those negative sort QX, I with another improvement a we'd the you digit of pointed the be prepared that the for we in little quarter. as mid-single the out, return market mentioned the bit to

Sachs. the The next from Matt line Sykes from today Goldman comes of question

wanted Prahlad, Maybe, start to you. for

touch portions you in covering gaps of of out made As both are acquisitions your how you Are academic think of gaps, in there you majority needs look number the is the feel you their do And that terms might the you at playing the organic solution, the R&D Just that of if and researchers the capturing do you in workflow Or and on love the think do you've gaps? biopharma? through spend along to inorganic And business, synergies segment of get where thoughts of points workflow? early that. because see an and way are you're Life solution? the customer customers would their those there lose in Sciences offering? your

Great question.

concept I think the whole a journey biomolecule acquisition And gaps and if portfolio that it on molecules, portfolio. that we gene the Nexcelom differentiation have gone to recall, I what through years from through on SIRION, in around and research fill the mean synergies our our of we development. seeing the And primarily table. fill in acquisition was the cell research our and molecule you think our portfolio whole was the is Horizon, journey we large the of and side had therapy. preclinical BioLegend X -- have went to transformation was preclinical gaps biomolecule, started the indeed portfolio ago, small I in that we

portfolio we we we feel there we if I very us that have we will that additions add think with with we continue the think are to allows But more I have. make? -- built. component good Absolutely. Will So we the feel where and are, the other portfolio that that software good very you good feel differentiation, very

how diagnostics growth ImmunoDX, progress about, And diagnostics and within in recovery, are through on that we about you then, growth phasing as to, different your that for the Sciences. specifically, specifically And then of thinking just of thinking business are framework? some there's phasing guidance XXXX terms has you how types China, comps on Great. of relative Max, maybe, Life year,

the be, would a roughly think, standpoint. from I first I half the So flat say diagnostics perspective, from ramps diagnostic will

weakness. have remember, throughout Life the and if So big year the -- through you the applied have purchases still Sciences we'll going headwinds as we the additional continued genomics COVID are we the in

business. the flattish half about mid-single-digit the And anticipating first so second it for a then will and growth Diagnostics return we're be for half to

China, In terms for is of your our growth. mid-single-digit immunodiagnostics, question year there full on the assumption

actually change what the one was still exclude the high similar infectious in China. The overall, to little in made of the in had double-digit our in we us, in a that improve it though the we was legacy change of impact you is come range. to growth low bit legacy XXXX it a strategy revenue of hit a will a if for single However, And disease to business of perspective. go-to-market profitability terms the there with of businesses why reason from

question from Waldman comes of Josh Cleveland from line next The the today Research.

you. Two for

those quite QX. Curious what's you did come maybe see November didn't And pullback I Prahlad were then and could businesses in mean, you're flushing were business. context you either seeing budget Science if came you bit maybe Life than pharma see broadly, in Or Life those First, through? Max, both the like or business, instrument guided Science you in wonder if the provide you you more applied on genomics, from thinking guess 'XX? better expecting? the what I looks for in instrument a and December I of when some it both assumed

Yes. Josh.

you applied at So on your instrumentation to both say fourth look point, the genomics I Life results, expectations. if a would Sciences the than quarter bit standpoint our better and fared

although little it into assumptions to fourth think those wouldn't that conservative, mentioned really and quarter, call be a were be slightly more we so did quarter. budget was were better. a and bit activity we wanting conservative we I there prove out in our on the flush they the to had coming instrumentation

look both pressured year. So instruments And as and I look instruments assumptions, we think a look X- out -- will at in the single-digit to LRP or that overall for to be the XXXX, high still over what the we X-year will XXXX, at in is line down this over if our Life when closer be put you for that believe them genomics Sciences do period. range you and applied will the their

Got it.

or then, how key more to seeing towards divestiture commercial realize to you're it as any you relates point examples the I you strategic Okay. talk specifically cross-sell a can partner, accounts about any within to Revvity's there being of effective guess, is are specific can momentum making progress rebranding? in following and Prahlad, And synergies ability Revvity pharma?

them, customers, the it of as the be the lab able how then Yes, I relationship drug example our care of are January, Josh, service through of that and in on of from our I only conferences Life for both licensing and those and pharma side them and of one preclinical important Omics the way tools the development capabilities earlier capabilities to not drug allows allows to think providing journey and the side in of the part take development about and of Sciences they to to customers for leverage global up of offering our most the from with part able for our important our with them portfolio technology, and that then their on, and and our health technology the follow-ups. one from side but drug to to patients approval that being that the side technology Diagnostic through development business is leveraging leverage the further regulatory the DX and we license during also use both being infrastructure the follow talked research, the the efficacy processes mentioned tools them them for all we provide the journey that towards process

So of imaging on and were us their molecule in when do tools providing that initially, components. was them focus just reagents small our side Science, Life and with in-vivo allows and instruments sort We the on we research. --

it to expansion with them commercialization. start to gets portfolio, full of to the Now, with from our it allows us when the be

The today line of Patrick Citi. Donnelly comes from next from question the

given XX this Did there. And on process you Probably this a Can you're It some guys just the What side. that guys Max, you piece that like expansion the year, key revisiting you you I understand it? into near saw want talk profitability maybe China business implement the there. in confidence as Even to talked more revenue see sounds about path continuing set where algorithm. to the just you bps for margin relative you executing a outlook. about term. that JPM? it just that more the one percent margin guys went plans clear XX-plus algorithm chasing are in that more on flattish becoming floor like levers the to and cost are the sounds at

of kind back a just maybe again, So little pull guys the the set. algorithm that curtain you margins on and,

Patrick. sure, Yes,

that So step of top just previous it points, think taken I was attributed, think, we perspective, points, in and was change basis it XX the XXX mostly as margin to a that line the down XX MRP look and the to I from from back basis at assumptions.

couple If a the of leverage hundred better that. just is drive you look at points assumption to pure from market average basis on perspective. going to a X%, of operating natural we're growing X% the That's growth than

what the business of of so early as sort as divestiture. the that, And of given be, processes this the them structure sort core to related and in and in the fact innings of to all the costs all confidence integrating still right? overall is In we're should the still number in well working even our of terms of think into through way expansion, margin have addition that the I acquisitions actual really the company we where our transformation, stranded

So in of expansion margin op I you or irons the an the just would get. -- a fire leverage lot think stokes standpoint volume from have natural we outside of

of or a is is terms it on consistently there floor, And I I can whether terms a we a we degree of the was deliver think expected growth that in conservative algorithm. that with fair of thought think in number confidence. high question amount your it's

but just China, little the about Prahlad, you in it just a Diagnostics some helpful. more which Science sounds term. ImmunoDX just side, But Again, talked is variable. confidence both guys profitable Life that business, earlier here in question. outlook an terms then like and guys making you on you're obviously in it a That's on China, maybe year, the sounds after of a confidence seeing the in like there, going the on this and region near Okay. of what you're seeing little little what changes are more terms

Patrick. Yes,

comes in we confidence the mean we to at the that portfolio play because changed where a really down this our China understanding of markets segments is and the out of if have market. and it I differentiation. nothing's built I look regarding that that there. of think where you think good level in portfolio I And is just the view over

on In the But will reagent terms markets. it I some coming continue to which Life I we side, think, we Sciences side, of pressure, other see to not is continue global think from will different the on the see instrumentation very back. side,

is about immunodiagnostics on side, that Max growth small it a the a On improve for continued us of talked to trajectory. business helps I profitability, the legacy excluding impact what think going be

impacted, get awaiting got reagents quite for decline. rate will the pressure are our approval. see birth hopefully, that NMPA compensate a that to few the we going but will they is screening And Newborn of we've from

of Sciences of again So, of it the going in in China outside of, longer it our will have. the be sort that is Life China. we Diagnostics, portfolio, both to to the -- exposure the the overall, I back risk The the and which advantage and think differentiation sort comes lower competitive run, to software portfolio market, mitigates our

today James. line Andrew of question next the from Raymond The Cooper from comes

about talk little I first, year. Maybe, for this just margins to a more bit want

organic growth. You have modest top line

You've bps actions. from cost coming got some XXX price,

what's to that different expansion? see prevent what asking guess, way, expansion some 'XX? maybe growth margin a you threshold I revenue of So, little counterpoints need of bit the in to see in it are of to maybe year-over-year a Or actually the

will some Yes. XXXX discussed already alone that that industry costs heard I of that XXXX. we Andrew, previously dynamic as for you've do returning as didn't I And the we is have think, we the fact in the others not in are we you have that mentioned, previously are in dynamic, it. believe one mention mentioned variable the

think we taking. and that's offsetting your So what's actions to really point, cost the the perspective, from been have that that price structural I

out But it from some have assumes, where don't a growth you expansion, margin model even environment anticipate I costs, able again, a think longer is I As driver lower earlier volume normal term, standpoint. in I say, the would would a us margin heavy say, a you to points. about more expansion still would my you with, LRP of look variable that drive being snapback when than the of given

Okay. really cost of rollout. in And moving one has early we then we about Any Helpful. retention, about on like maybe the e-commerce whether terms just you on the are looked what the feedback more of what it's and benefits can just as sort there that share or metrics U.S. globally think think side, beyond and how the rollout term? customer the longer rollout

so it. good the and to it in just Yes, on it, launch of Andrew. in I out seeing the we MVP days out OUS mean, as mid-December, a of perspective, be it's quarter. ], the flow customer [ rolled traction we is early early mentioned second we from part the expected are

while ahead X it's early of still is So it and say to I X would looks months schedule, days promising.

cost portfolio offer a of over I common that to able from platform, to or an get being the of OpEx synergistic that perspective our perspective. obviously, the get is a opportunities think, you comprehensive it benefit synergies but, our the on out we customers longer just not term,

early way best what hearing we very I So is seeing, but would and it now. excited the we are are for about days frame

today comes Baird. question from of line the Schulte Catherine from next The

the Maybe, businesses some dynamics. to first, due and genomics contract software renewal timing year last have and your lab faced headwinds project over

can expect walk you through both those you the kind quarter mentioned those for of You the and in normalizing us from the what performance just and full timing first year? businesses, there 'XX, but

Yes. Sure, Catherine.

if market, and hundred couple we're look a above about is So guidance market to way more overall. we of business. I XXXX. it we sort get about assuming digits step of Revvity low points Omics of the then our single at in back that software the down -- flat holistically, think so is to And X% think maybe take just way think of as here the call a normalization the that and basis grows we sort

a about tailwind XXX specific it's this basis So for year. Revvity point

declined little in the that to and XXXX In assumptions Omics bit business, a digits XX% single high those business, the those be terms signed. the was contracts expect individual that get for for in it essentially, XXXX, flat businesses so, XXXX, return of than of none down we in assuming are for more software growth XXXX to new high-single-digits we expecting to in it and

deals, guidance case that on assumed have be the to upside would We business. continue And if that we to here. to remain encouraged we're by the able for those pipeline of close in some what's

AES how particularly then back outflows cash should And think about to Great. flow those in with Okay. we coming free XXXX, you?

Yes.

perspective, we by quarter. in the that again, cash encouraged the from a fourth results here flow So had are we

year, for overall roughly about meant that million the normalize once more those than AES For $XXX would outflows. have you

cash As as we look will $XXX is cash to anticipation The free outflows inflows to generation XXXX, our of about investing us flow. back actually flow come AES million. in

$XXX to If of overall in are generation add million cash million, the $XXX XXXX. we to targeting have you that about

question ISI. comes Kumar next The the line from Evercore today Vijay of from

you for comps. on it the one call you my mid-singles, Maybe did QX of first organic guidance assumption down

half singles perhaps low just low down QX look be assuming jump down driving singles. talk peers your Most to offs. mid-singles. are change QX, what's first down to You that to of why from maybe And at similar sequentially

Yes.

from a about, year. talked a to it obviously, of we comps we perspective, lot a the as last had that think, I QX is, QX from

an allocate nothing than is do from it timing out that. else. the for impact of year, where I XQ China. instrument more I And is impact I that have of is say. anything laid of on else. of we that calendar that, as cadence is outside But health, the we Max to So it pressure anything would there the versus on more that impact would than will some especially the And the see some side, just reproductive see else, think, anything it We in

the printed I'd single what what first half to for quarter. add fourth that it is the that QX, only Vijay, we you Most saying what I are that, digits, half point similar which to line with they the just just and be I assumption Yes. will had mentioned mean, that's our yourself, in in mentioned right, is first previously, down right? low

Understood. versus fiscal about gross down QX be you, maybe think the flattish, sequentially, is when 'XX? assuming QX? And, gross 'XX happened guide margins in fiscal for guide, in margins what or Max, And your so one down up to you

Yes.

Vijay, on the I just -- asking the you were question might year. margin this first your for I missed question, gross Sorry, have part mentioning of think

fourth So quarter. about was gross play dynamics quarter-over-quarter the mix was the some fourth margin as in had the in down quarter, we out XX%. It

we to we expect XXXX, year-over-year, increased full throughout look be volume build we get to expect it As to year year. as gross we the and goes flat leverage year roughly margin the on as

like the driving essentially, the QX? that step-up assumption, what's is from improves, And so, Max, the mix

Yes.

similar I similar. think, dynamic it's mix kind from QX. QX relatively We're to of a to expecting QX, from QX

as rest a As the of leverage to opposed year volume progresses, the change mix is dynamics. massive story a it mostly in

the line Dan The from Cowen. next of from comes TD today question Brennan

outcomes of growth? ImmunoDx, for of the like solid in kind So just us expect a quarter strong sense 'XX? And year. what's can another what's Can you driving the the give of range we

as be China limited think, that Dan, of in continue has see competition in the we that as EUROIMMUN face I've allows look differentiated portfolio that have us that pipeline high-end it we to in forward. I -- again, we And has worked innovation earlier, we expect talked the us, to marketplace. for of that test is that about the and

Got it.

it on pharma. a QX. drag but you throughout a in key I little kind Maybe was of about it bit, talked know Okay.

pressure guys here, about under from still talked high. You maybe instruments post-COVID a

your you this there. more of year? what any can Just expect you're do on kind hearing pharma, of with what color speak discussions to kind some Just of we

Yes, Dan.

in continue half we I think least we it instrument the I this the or at in past the we some would we the assumption have growth the as capital to then, we continue over year, believe think, come back I at that I pattern allows second in least that again, marketplace, the our what to think, forecast portfolio, trend, that's and will Overall, benefit, allows of up it mid-single-digit pharma, to years. of will continue the in temporary to half -- will confidence it first trough the is that expect on the The several pressure current that year. the have we stabilizing or us side, look. and is see that side us starts on the in market is that side a see the seen of that reagent of normal to what once the continue current coming

the from Burstein question next Bernstein Research. today line of from The Eve comes

actions said And in benefits you ability 'XX, and some those what's on one, First cost be achieve you'll to what structural taken giving give confidence you more that those actions the you've far measures year color are? this so you this frame? already taking time cost additional can in us just in

Yes.

easiest integration that's we mentioned standpoint. So which the way working acquisitions, still structural costs in would a our the transformation, from from way from stranded action company, the And it's a of of it consider cost to then perspective, think to divestiture. what the given process the early about really all I we're the is mid-innings the through whether the rightsizing just

really that's what's structural actions. driving So the cost

a cost the actions throughout the point. year, actual place when been been bit and communicated. have or comes actions the of in a of of timing executed but out just little those the already timing terms it's more matter In already course this There's taken terms of less of confidence, those and at have

this year. confidence of in would I high have, we degree So say, a those for

And just talked integration of Great. your you acquisitions. then about

you in Where mid-innings. how the would BioLegend, against way synergy yourself $XXX X/X example year, are to through. still You You're of scale? other X? the your brought target said you your of that you of also really to with of together But really do on it's business, year cool. of an X/X put Where million something parts you shared early

the just of the quantify are what we dollar provided from also not -- synergies an think to is I'm how technological going and as commercial don't what's The not portfolio, Yes, we example I'm operational we how I seeing. to as full synergies. to intent are synergies much see starting but of amount

from Keep and And provide I to then crown integration and of BioLegend our expect strongest them would in opportunities the Max I of said, see are early mind, the well. businesses. EUROIMMUN we acquisitions, of I our mid-innings X continue in the to our think, are they that acquisitions. opportunities still X think we fastest-growing as say and perform we that to the in of portfolio jewels are

how those intent them? we see Our with that across is support we the portfolio how leverage businesses do we opportunities the do and

Luke the Sergott line of Our Barclays. final question from today comes from

quick XQ margin So real the target. on

your basis You points lower said like a few year. than hundred full

talk like that and what's and bit Can the about, going you driving around can throughout a where you talk looks you're So everything kind that's on growth like even though really ramp? assume I get XQ, steep to the little just that about then year the of XX%. uplift margin decel

Yes, Luke.

tackle think first kind question I that. you led of as let's just the So with maybe margin

I your the math don't going to given we've look, number. that is to roughly and line think think get QX I that off pieces So far you you're from QX below the in that

As say volume that would main X a you top perspective. -- the look step-down from the comparing really a main is line driver that at QX, I to just of

gross roughly at actual quarter-over-quarter. the percentage, flat If quarter-over-quarter. costs overall it's in you are OpEx line margin similarly look

the remainder to to think of much volume the has year And structural ramp going don't as cost play. over that we as really you're the look into you're the in of from the have one, the I timing mentioned, standpoint, coming is second so, piece changed. builds. you year, leverage Again, And at going have then as the actions volume

would it So from I about margin a perspective. that's how think

slowdown We've to our immunodiagnostics sort comp-driven. that the of think on China grew the is an Outside and said of business definitely to the I we've of last the there double mentioned teens. part biggest normalization for in of half of outside outside should going In perspective just business QX, growth organic immunodiagnostics be digit some always first a be China. And of from is China. it the is stack piece so there in immunodiagnostics QX low of terms high year, a X-year between that

lumpiness that guess, the talk software XQ and seeing you're SaaS framework more inflecting the on will have to Great. steep in decline the can a on prior, just like XQ X% And have I come talked the that the these based, is referring you because, next -- the of And a were aiming about the points core on -- got orders, margin. talking reduce way of you the as lift. then be about the a that just non-SaaS if what then, guys converting of of or there look just the lot kind and piece, XXX similar to at commentary. I software just I customers orders about not gave pretty you progress the to you about least basis that's kind talked talk to piece, they're the you contracts and if there. headwind that year and was

Yes.

Luke. second question So start I'll maybe with your first,

that's high up moving as growth in basis what's business our from digits single organic single company to high It down be digits, 'XX. that the was assumed So software is points XXX I mentioned, of 'XX for overall an roughly guidance in should perspective. here

Again, dynamic, And that's really has you renewal so this upper-XXs-percent rate. renewals. at look it's contract a business that that driven as by

good first our have SaaS transition. of know them terms is we continue contracts the I We actually for question the our in to they're We to transition of view confidence on deliver ability a differentiator would believe in most so we think to 'XX versus make ahead progress. we to due, coming transition, our sort degree really I peers. high say, SaaS And us the are your and of on a then of expectations. And that of

that SaaS business although noise for help standpoint, it is we the right a And think from to take little our and recognition so, the thing of actually competition. bit to are a do products us our create revenue might from share going

term, a another the revenue us definitely increase in which the look, perspective. of And Yes. reduce opportunities volatility is from the that us differentiation business our that one provides business, I software help longer and for think it

back session. for any to pass today's Willoughby I'd the over concludes like remarks. closing question-and-answer Steve call This to

questions forward good Thank today, you. coming further weeks. a interest we the Have and to Thanks look day. discussions over for your and Bye-bye.

conference concludes Thank you This today's participation. your all call. for

may lines. now your You disconnect